IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
The sale of remaining rights to Allogene ends acrimony between the two companies.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
Keyvibe-010 fails, but not for the reason you might have expected.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.
But the group’s attempt to join Janux at the high altar of masking technology falls flat.